Breaking News Instant updates and real-time market news.

AFMD

Affimed N.V.

$2.97

-0.45 (-13.16%)

13:16
06/24/19
06/24
13:16
06/24/19
13:16

Affimed falls 13% after announcing clinical update on AFM13 in CD30 lymphomas

Earlier today, Affimed announced the presentation of data updates on two clinical studies at the 15th International Conference on Malignant Lymphoma, ICML, in Lugano, Switzerland. The data from an oral and a poster presentation featured Affimed's lead innate cell engager AFM13, a first-in-class tetravalent, bispecific antibody derived from the ROCK platform that is being developed to treat CD30-positive lymphomas. AFM13 specifically binds to CD30 on tumor cells and to CD16A on innate immune cells, such as NK cells and macrophages. "The results of the completed Phase 1b study of AFM13 in combination with pembrolizumab in Hodgkin lymphoma and of Columbia University's study of AFM13 in patients with relapsed or refractory CD30-positive lymphoma with cutaneous presentation substantiate the potential of AFM13 to make a difference in the lives of patients with limited to no treatment options," said Dr. Leila Alland, Affimed's Chief Medical Officer. "We look forward to advancing our innate cell engagers in future clinical studies, including our registration-directed study of AFM13 in relapsed and refractory peripheral T cell lymphoma and transformed mycosis fungoides." Shares of Affimed are down 44c per share or 12.76% to $2.98 in afternoon trading.

AFMD Affimed N.V.
$2.97

-0.45 (-13.16%)

09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
10/09/18
RHCO
10/09/18
NO CHANGE
Target $5
RHCO
Buy
Affimed N.V. price target lowered to $5 from $7 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Affirmed to $5 after the FDA placed a clinical hold on its T cell engager AFM11 phase 1 trial. The analyst keeps his Buy rating on the shares however, saying he sees no read-through to the company's NK cell engager platform or any impact on the recent NK cell engager Genentech deal. Lawson adds that commentary from the management indicates that the "series adverse events" in the study hold are "likely drug-related and from a CD19-related neurotoxicity" and should not impact the ongoing development of AFM13.
10/09/18
BMOC
10/09/18
NO CHANGE
Target $5
BMOC
Outperform
Affimed N.V.'s clinical trial hold on AFM11 'likely temporary', says BMO Capital
BMO Capital analyst Do Kim kept his Outperform rating and $5 price target on Affirmed N.V., saying the clinical hold placed on its AFM11 phase 1 trial is likely to be "temporary" since the three "serious adverse events" cited were identified as neurotoxicities. While he lowers his probability of success in acute lymphoblastic leukemia to 25% from 30% and keeps his probability in non-Hodgkin lymphoma at a "low" 15%, Kim calls for investors to buy Affirmed shares on weakness since the clinical hold is not likely to become "program ending".
03/28/19
LEER
03/28/19
INITIATION
Target $8
LEER
Outperform
Affimed N.V. initiated with an Outperform at SVB Leerink
SVB Leerink initiated Affimed with an Outperform and $8 price target.

TODAY'S FREE FLY STORIES

CHKP

Check Point

$115.70

0.44 (0.38%)

05:42
07/24/19
07/24
05:42
07/24/19
05:42
Earnings
Check Point reports Q2 EPS $1.38, consensus $1.37 »

Reports Q2 revenue $488M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 03

    Aug

PSTI

Pluristem

$0.57

-0.0209 (-3.55%)

05:40
07/24/19
07/24
05:40
07/24/19
05:40
Hot Stocks
Pluristem announces 1-for-10 reverse stock split »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLBK

Old Line Bancshares

$26.14

(0.00%)

, WSBC

WesBanco

$37.73

0.49 (1.32%)

05:32
07/24/19
07/24
05:32
07/24/19
05:32
Downgrade
Old Line Bancshares, WesBanco rating change  »

Old Line Bancshares…

OLBK

Old Line Bancshares

$26.14

(0.00%)

WSBC

WesBanco

$37.73

0.49 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 11

    Sep

  • 23

    Sep

WIX

Wix.com

$146.25

0.8 (0.55%)

05:26
07/24/19
07/24
05:26
07/24/19
05:26
Earnings
Wix.com raises FY19 revenue guidance to $761M-$765M from $758M-$763M »

Consensus $762.02M.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

CPAC

Cementos Pacasmayo

$8.60

(0.00%)

05:25
07/24/19
07/24
05:25
07/24/19
05:25
Upgrade
Cementos Pacasmayo rating change  »

Cementos Pacasmayo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIX

Wix.com

$146.25

0.8 (0.55%)

05:24
07/24/19
07/24
05:24
07/24/19
05:24
Earnings
Wix.com sees Q3 revenue $196M-$198M, consensus 196.25M »

Sees Q3 collections…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

ADYYF

Adyen

$0.00

(0.00%)

05:23
07/24/19
07/24
05:23
07/24/19
05:23
Initiation
Adyen initiated  »

Adyen initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIX

Wix.com

$146.25

0.8 (0.55%)

05:23
07/24/19
07/24
05:23
07/24/19
05:23
Earnings
Wix.com reports Q2 EPS 34c, consensus 18c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

SNAP

Snap

$14.85

0.71 (5.02%)

05:22
07/24/19
07/24
05:22
07/24/19
05:22
Upgrade
UBS upgrades Snap to Neutral, doubles price target to $16 from $8 »

UBS analyst Eric Sheridan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

PRTY

Party City

$5.56

-0.005 (-0.09%)

05:17
07/24/19
07/24
05:17
07/24/19
05:17
Upgrade
Party City rating change  »

Party City upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$12.11

0.16 (1.34%)

, LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

05:15
07/24/19
07/24
05:15
07/24/19
05:15
Upgrade
Lionsgate, Use LGF.A, LGF.B rating change  »

Lionsgate upgraded to Buy…

LGF.A

Lionsgate

$12.11

0.16 (1.34%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

PHM

PulteGroup

$30.73

-2.74 (-8.19%)

05:13
07/24/19
07/24
05:13
07/24/19
05:13
Upgrade
PulteGroup rating change  »

PulteGroup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$135.06

0.66 (0.49%)

05:12
07/24/19
07/24
05:12
07/24/19
05:12
Upgrade
Kimberly-Clark rating change  »

Kimberly-Clark upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEG

Leggett & Platt

$40.18

0.63 (1.59%)

05:11
07/24/19
07/24
05:11
07/24/19
05:11
Downgrade
Leggett & Platt rating change  »

Leggett & Platt…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 07

    Aug

  • 08

    Aug

SWMAY

Swedish Match

$0.00

(0.00%)

05:10
07/24/19
07/24
05:10
07/24/19
05:10
Downgrade
Swedish Match rating change  »

Swedish Match downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$0.00

(0.00%)

05:09
07/24/19
07/24
05:09
07/24/19
05:09
Downgrade
UniCredit rating change at UBS »

UniCredit downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLDP

Ballard Power

$4.06

0.02 (0.50%)

05:07
07/24/19
07/24
05:07
07/24/19
05:07
Hot Stocks
Ballard Power announces order from Wrightbus for 15 fuel cell modules »

Ballard Power announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

HSBC

HSBC

$41.64

0.21 (0.51%)

05:06
07/24/19
07/24
05:06
07/24/19
05:06
Downgrade
HSBC rating change  »

HSBC downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$60.55

-0.2 (-0.33%)

05:04
07/24/19
07/24
05:04
07/24/19
05:04
Downgrade
Rio Tinto rating change  »

Rio Tinto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MPW

Medical Properties Trust

$17.67

0.12 (0.68%)

05:02
07/24/19
07/24
05:02
07/24/19
05:02
Upgrade
Medical Properties Trust rating change  »

Medical Properties Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$245.89

-3.31 (-1.33%)

04:59
07/24/19
07/24
04:59
07/24/19
04:59
Downgrade
Trade Desk rating change  »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

SNAP

Snap

$14.85

0.71 (5.02%)

04:58
07/24/19
07/24
04:58
07/24/19
04:58
Upgrade
Snap rating change  »

Snap upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

NRDBY

Nordea Bank

$0.00

(0.00%)

04:57
07/24/19
07/24
04:57
07/24/19
04:57
Downgrade
Nordea Bank rating change  »

Nordea Bank downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JLL

Jones Lang LaSalle

$142.91

3.105 (2.22%)

04:55
07/24/19
07/24
04:55
07/24/19
04:55
Conference/Events
Jones Lang LaSalle management to meet with Mizuho »

Meeting with EVP Monahan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

AGLE

Aeglea BioTherapeutics

$6.91

-0.05 (-0.72%)

04:55
07/24/19
07/24
04:55
07/24/19
04:55
Conference/Events
Aeglea BioTherapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.